Pancreatic Cancer Research

ResearcherJohns Hopkins UniversityActive in the last 2 years

Daniel Delitto

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-2838-5841; OpenAlex author ID A5011787316; NIH RePORTER profile ID 11913241. Sources: OpenAlex.

Their work

Papers
27 (first author 3, last author 2)
Trials
0
Grants
1
Labs led
1
Collaborators
71
Papers, trials and grants by year

2014: 1 paper · 2015: 3 papers · 2016: 3 papers · 2017: 4 papers · 2018: 2 papers · 2019: 1 paper · 2020: 3 papers · 2021: 2 papers · 2022: 1 paper · 2023: 1 paper · 2024: 2 papers · 2025: 1 paper · 2026: 3 papers, 1 grant

Papers 27

  1. NFAT mediates pro-tumorigenic inflammation in cancer-associated fibroblasts in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.celrep.2025.116849↗
  2. Protocol for orthotopic implantation of a collagen hydrogel to model pancreatic ductal adenocarcinoma in mice. Last author DOI 10.1016/j.xpro.2025.104337↗
  3. Biochemical, Radiographic, or Pathologic Response to Neoadjuvant Chemotherapy in Resected Pancreatic Cancer: Which Is Best? Co-author DOI 10.1097/sla.0000000000006609↗
  4. Disruption of fibroblast MYD88 signaling promotes antitumor immunity in pancreatic ductal adenocarcinoma. Last author DOI 10.1016/j.celrep.2025.116347↗
  5. Hematoxylin and Eosin Architecture Uncovers Clinically Divergent Niches in Pancreatic Cancer. Co-author DOI 10.1089/ten.tea.2024.0039↗
  6. Fibroblasts in the Aged Pancreas Drive Pancreatic Cancer Progression. Co-author DOI 10.1158/0008-5472.can-24-0086↗
  7. Desmoplastic stromal signatures predict patient outcomes in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.xcrm.2023.101248↗
  8. Postoperative Chemotherapy is Associated with Improved Survival in Patients with Node-Positive Pancreatic Ductal Adenocarcinoma After Neoadjuvant Therapy. Co-author DOI 10.1007/s00268-022-06667-x↗
  9. Impact of Margin Status on Survival in Patients with Pancreatic Ductal Adenocarcinoma Receiving Neoadjuvant Chemotherapy. First author DOI 10.1016/j.jamcollsurg.2020.11.018↗
  10. Implantation of a neoantigen-targeted hydrogel vaccine prevents recurrence of pancreatic adenocarcinoma after incomplete resection. Co-author DOI 10.1080/2162402x.2021.2001159↗
  11. Protein Signatures and Tissue Diagnosis of Pancreatic Cancer. Co-author DOI 10.1016/j.jamcollsurg.2019.10.002↗
  12. The role of survivin in the progression of pancreatic ductal adenocarcinoma (PDAC) and a novel survivin-targeted therapeutic for PDAC. Co-author DOI 10.1371/journal.pone.0226917↗
  13. Nicotine Induces IL-8 Secretion from Pancreatic Cancer Stroma and Worsens Cancer-Induced Cachexia. Co-author DOI 10.3390/cancers12020329↗
  14. IL-8 Released from Human Pancreatic Cancer and Tumor-Associated Stromal Cells Signals through a CXCR2-ERK1/2 Axis to Induce Muscle Atrophy. Co-author DOI 10.3390/cancers11121863↗
  15. Skeletal Muscle Fibrosis in Pancreatic Cancer Patients with Respect to Survival. Co-author DOI 10.1093/jncics/pky043↗
  16. Local and Systemic Cytokine Profiling for Pancreatic Ductal Adenocarcinoma to Study Cancer Cachexia in an Era of Precision Medicine. Co-author DOI 10.3390/ijms19123836↗
  17. A clinically applicable muscular index predicts long-term survival in resectable pancreatic cancer. Co-author DOI 10.1016/j.surg.2016.09.038↗
  18. Orthotopic Patient-Derived Pancreatic Cancer Xenografts Engraft Into the Pancreatic Parenchyma, Metastasize, and Induce Muscle Wasting to Recapitulate the Huma… First author DOI 10.1097/mpa.0000000000000843↗
  19. Human Pancreatic Cancer Cells Induce a MyD88-Dependent Stromal Response to Promote a Tumor-Tolerant Immune Microenvironment. Co-author DOI 10.1158/0008-5472.can-16-1765↗
  20. Human pancreatic cancer xenografts recapitulate key aspects of cancer cachexia. Co-author DOI 10.18632/oncotarget.13593↗
  21. Isolation of Pancreatic Cancer Cells from a Patient-Derived Xenograft Model Allows for Practical Expansion and Preserved Heterogeneity in Culture. First author DOI 10.1016/j.ajpath.2016.02.009↗
  22. Targeting tumor tolerance: A new hope for pancreatic cancer therapy? Co-author DOI 10.1016/j.pharmthera.2016.06.008↗
  23. Nicotine Reduces Survival via Augmentation of Paracrine HGF-MET Signaling in the Pancreatic Cancer Microenvironment. Co-author DOI 10.1158/1078-0432.ccr-15-1256↗
  24. Downstream mediators of the intratumoral interferon response suppress antitumor immunity, induce gemcitabine resistance and associate with poor survival in hum… Co-author DOI 10.1007/s00262-015-1760-y↗
  25. Patient-derived xenograft models for pancreatic adenocarcinoma demonstrate retention of tumor morphology through incorporation of murine stromal elements. Co-author DOI 10.1016/j.ajpath.2015.01.016↗
  26. The inflammatory milieu within the pancreatic cancer microenvironment correlates with clinicopathologic parameters, chemoresistance and survival. Co-author DOI 10.1186/s12885-015-1820-x↗
  27. c-Met signaling in the development of tumorigenesis and chemoresistance: potential applications in pancreatic cancer. Co-author DOI 10.3748/wjg.v20.i26.8458↗

Grants 1

  1. Reprogramming inflammatory fibroblasts to overcome therapeutic resistance in pancreatic adenocarcinoma R37CA311069↗

Closest collaborators

The 25 strongest of 71 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Steven J. Hughes · 14 shared papers, 2015–2024 · strength 1.04
  2. Deshka S. Foster · 5 shared papers, 2023–2026 · strength 0.97
  3. Michael Thornton Longaker · 5 shared papers, 2023–2026 · strength 0.97
  4. Jose Gilberto Trevino · 14 shared papers, 2015–2020 · strength 0.96
  5. Jeffrey Allen Norton · 5 shared papers, 2023–2026 · strength 0.95
  6. Jason L. Guo · 4 shared papers, 2023–2026 · strength 0.70
  7. Maria Moozhiyil Korah · 3 shared papers, 2025–2026 · strength 0.66
  8. James Paul Agolia · 3 shared papers, 2025–2026 · strength 0.66
  9. Chuner Guo · 3 shared papers, 2025–2026 · strength 0.66
  10. George A. Poultsides · 3 shared papers, 2025–2026 · strength 0.63
  11. Brendan Christopher Visser · 3 shared papers, 2025–2026 · strength 0.63
  12. Michael H. Gerber · 7 shared papers, 2017–2020 · strength 0.56
  13. Sarah M. Judge · 7 shared papers, 2017–2020 · strength 0.56
  14. Andrew R. Judge · 7 shared papers, 2017–2020 · strength 0.56
  15. Ryan Michael Thomas · 9 shared papers, 2015–2020 · strength 0.54
  16. Song Han · 6 shared papers, 2015–2024 · strength 0.52
  17. Shannon Margaret Wallet · 9 shared papers, 2015–2018 · strength 0.52
  18. K.E. Behrns · 9 shared papers, 2015–2017 · strength 0.49
  19. Thomas J. George · 8 shared papers, 2015–2017 · strength 0.44
  20. Byrne Lee · 2 shared papers, 2025–2026 · strength 0.42
  21. Amanda Kirane · 2 shared papers, 2025–2026 · strength 0.42
  22. Chen Liu · 7 shared papers, 2015–2020 · strength 0.39
  23. Jin Peng He · 3 shared papers, 2021–2022 · strength 0.35
  24. Richard Andrew Burkhart · 3 shared papers, 2021–2022 · strength 0.35
  25. Shamik Mascharak · 2 shared papers, 2023–2024 · strength 0.31

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.